589 related articles for article (PubMed ID: 17691763)
1. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
3. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
Mai A; Massa S; Rotili D; Simeoni S; Ragno R; Botta G; Nebbioso A; Miceli M; Altucci L; Brosch G
J Med Chem; 2006 Oct; 49(20):6046-56. PubMed ID: 17004718
[TBL] [Abstract][Full Text] [Related]
5. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
[TBL] [Abstract][Full Text] [Related]
6. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
Su H; Nebbioso A; Carafa V; Chen Y; Yang B; Altucci L; You Q
Bioorg Med Chem; 2008 Sep; 16(17):7992-8002. PubMed ID: 18701301
[TBL] [Abstract][Full Text] [Related]
8. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
[TBL] [Abstract][Full Text] [Related]
9. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
[TBL] [Abstract][Full Text] [Related]
12. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
Lu Q; Wang DS; Chen CS; Hu YD; Chen CS
J Med Chem; 2005 Aug; 48(17):5530-5. PubMed ID: 16107152
[TBL] [Abstract][Full Text] [Related]
13. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
15. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
16. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
Moradei O; Leit S; Zhou N; Fréchette S; Paquin I; Raeppel S; Gaudette F; Bouchain G; Woo SH; Vaisburg A; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Li Z; Rahil J; MacLeod AR; Besterman JM; Delorme D
Bioorg Med Chem Lett; 2006 Aug; 16(15):4048-52. PubMed ID: 16713259
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
18. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]